Metheor Therapeutics
Shoreline
About Metheor Therapeutics
Metheor Therapeutics Corp is a biotechnology company designing and developing inhibitors of DNA methyltransferase enzymes (DNMTs). Our goal is to produce novel therapeutic compounds that will have a role in the treatment of cancers and other major diseases. While there are two approved DNMT inhibitors being used to treat Myelodysplastic Syndromes (Vidaza and Dacogen), there is a need for new treatments with selective pharmocology and improved toxicity profiles. Our novel approach addresses this need.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $185.0K
- Funding stage: Seed
- Last round: Seed (Aug 2011)
- Website: metheorx.com
- Phone: (206)546-346
Industries & Categories
Biotechnology, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/metheor-therapeutics-2442835 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.